Advertisement

Picture EBD Group World of Partnering Opportunities 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 3468 | Ordered by Date (descending)
next pagenext page 1 2 3 4 ... 33 34 35  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Vandria–SEVERAL: investment, 202312 emerges from stealth with financing round Series A CHF18m led by +ND Capital 2023-12-14
Tome Biosciences–Bruker: investment, 202312 financing rounds Series A + B totalling $213m incl investor Bruker Corp 2023-12-12
Tome Biosciences–SEVERAL: investment, 202312 financing rounds Series A + B $213m announced at launch 2023-12-12
Zafrens–BY Capital: investment, 202312 company emerges with total of $23m in financing incl co-investor BluYard Capital 2023-12-11
Zafrens–SEVERAL: investment, 202312 company emerges with $23m in financing led by Prime Movers Lab 2023-12-11
Eligo Bioscience–Sanofi: investment, 202312 financing round Series B totalling $30m incl new + lead investor Sanofi Ventures 2023-12-05
Eligo Bioscience–SEVERAL: investment, 202312 financing round Series B $30m led by Sanofi Ventures 2023-12-05
Odyssey Therapeutics–BlackMars Capital: investment, 202312 financing round Series C totalling $101m incl co-investor BlackMars Capital 2023-12-05
Odyssey Therapeutics–HBM: investment, 202312 financing round Series C totalling $101m incl existing + co-investor HBM Healthcare Investments 2023-12-05
Odyssey Therapeutics–SEVERAL: investment, 202312 financing round Series C $101m led by Ascenta Capital 2023-12-05
Carmot Therapeutics–Roche: investment, 202312– acquisition $2.7b upfront + $400m milestones by Roche 2023-12-04
WMT AG–FS Life Science Investment: investment, 202311 investment by FS Investment in WMT as part of current bridge financing 2023-11-28
WMT AG–High-Tech Gründerfonds: investment, 202311 existent HTGF is existing investor in WMT 2023-11-28
Evomedis–MC Services: public relations, 202311 service existent by MC Services 2023-11-23
T3 Pharmaceuticals–Boehringer: investment, 202311 acquisition of T3 Pharma for up to CHF450m by Boehringer Ingelheim 2023-11-22
Evolva–Lallemand: investment, 202311– acquisition of operations via 100% of Evolva AG for CHF20m + CHF10m milestones by Danstar Ferment AG 2023-11-21
RED Horticulture–ECBF: investment, 202311 financing round Series A totalling €17m incl new + lead investor ECBF 2023-11-21
RED Horticulture–SEVERAL: investment, 202311 financing round Series A €17m led by ECBF with Demeter IM + Unigrains 2023-11-21
Roche–Nvidia: AI-based drug r+d, 202311– collab strategic alliance multi-year of Genentech with Nvidia using Nvidia DGX Cloud + Nvidia BioNemo 2023-11-21
NMD Pharma–SEVERAL: investment, 202311 financing round Series B €75m led by existing investor Jeito Capital 2023-11-15
Glox Therapeutics–SEVERAL: investment, 202311 seed financing round £4.3m led by BIVF + Scottish Enterprise 2023-11-14
Nouscom–5AM Ventures: investment, 202311 financing round Series C totalling €67.5m incl existing + co-investor 5AM Ventures 2023-11-14
Nouscom–Andera Partners: investment, 202311 financing round Series C totalling €67.5m incl new + co-lead investor Andera Partners 2023-11-14
Nouscom–EQT: investment, 202311 financing round Series C totalling €67.5m incl existing + co-investor EQT Life Sciences 2023-11-14
Nouscom–France (govt): investment, 202311 financing round Series C totalling €67.5m incl new + co-lead investor Bpifrance InnoBio 2 Fund 2023-11-14
Nouscom–Indaco Venture: investment, 202311 financing round Series C totalling €67.5m incl new + co-investor Indaco Venture Partners 2023-11-14
Nouscom–Merck (DE): investment, 202311 financing round Series C totalling €67.5m incl new + co-lead investor M Ventures 2023-11-14
Nouscom–Panakès Partners: investment, 202311 financing round Series C totalling €67.5m incl new + co-investor Panakès Partners 2023-11-14
Nouscom–Revelation Partners: investment, 202311 financing round Series C totalling €67.5m incl new + co-investor Relevation Partners 2023-11-14
Nouscom–SEVERAL: investment, 202311 financing round Series C €67.5m led by Andera Partners + Bpifrance InnoBio 2 Fund + M Ventures 2023-11-14
Nouscom–Versant Ventures: investment, 202311 financing round Series C totalling €67.5m incl existing + co-investor Versant Ventures 2023-11-14
Nouscom–XGen Venture: investment, 202311 financing round Series C totalling €67.5m incl new + co-investor Xgen Ventures 2023-11-14
Novartis–GenScript: CAR-T cell therapies, 202311– license excl ww $100m upfront + $1.01b milestones + royalties for DLL CAR-Ts Legend Biotech 2023-11-13
Sallea–Venture Kick: grant, 202311 startup award CHF150k from Venture Kick 2023-11-13
Insempra–Germany (govt): grant, 202311–202610 innvoation grant €1.5m from SPRIND to advance BioTreasure prototype 2023-11-10
Valanx Biotech–Niederösterreich (govt): investment, 202311 growth financing totalling €2.3m equity + public funding incl existing investor TE 2023-11-07
Valanx Biotech–SEVERAL: investment, 202311 growth financing round €2.3m incl equity + public funding led by SkyGene 2023-11-07
Valanx Biotech–SkyGene: investment, 202311 growth financing round totalling €2.3m in equity + public funding incl new + lead investor SkyGene 2023-11-07
Valanx Biotech–SOSV: investment, 202311 growth financing totalling €2.3m equity + public funding incl existing investor SOSV 2023-11-07
Valanx Biotech–Xista Science Ventures: investment, 202311 growth financing round totalling €2.3m equity + public funding incl existing investor Xista 2023-11-07
HeartBeat.bio–SEVERAL: investment, 202311 financing round pre-Series A €4.5m with i&i Biotech Fund + Invest AG + aws + Tensor Ventures 2023-11-02
Memo Therapeutics–Adjuvant Capital: investment, 202311 financing round Series C totalling CHF25m incl existing + co-investor Adjuvant Capital 2023-11-02
Memo Therapeutics–Bellevue: investment, 202311 financing round Series C totalling CHF25m incl new + lead investor Pureos Bioventures 2023-11-02
Memo Therapeutics–Fresenius: investment, 202311 financing round Series C totalling CHF25m incl existing + co-investor Fresenius Medical Care Ventures 2023-11-02
Memo Therapeutics–GF Group: investment, 202311 financing round Series C totalling CHF25m incl existing + co-investor GFGroup 2023-11-02
Memo Therapeutics–Redalpine: investment, 202311 financing round Series C totalling CHF25m incl existing + co-investor Red Alpine 2023-11-02
Memo Therapeutics–Schroders: investment, 202311 financing round Series C totalling CHF25m incl existing + co-investor Schroders Capital 2023-11-02
Memo Therapeutics–SEVERAL: investment, 202311 financing round Series C CHF25m led by Pureos Bioventures to complete US phase 2 study with AntiBKV 2023-11-02
Memo Therapeutics–Verve Capital Partners: investment, 202311 financing round Series C totalling CHF25m incl existing + co-investor Verve Ventures 2023-11-02
Memo Therapeutics–Vesalius Biocapital: investment, 202311 financing round Series C totalling CHF25m incl existing + co-investor Vesalius Biocapital 2023-11-02
Memo Therapeutics–Zürcher Kantonalbank: investment, 202311 financing round Series C totalling CHF25m incl existing + co-investor Swisscanto 2023-11-02
Cambrium–Essential Capital: investment, 202311 seed financing round totalling €8m incl lead investor Essential Capital 2023-11-01
Cambrium–Hof Capital: investment, 202311 seed financing round totalling €8m incl co-investor Hof Capital 2023-11-01
Cambrium–Merantix: investment, 202311 existing investor Merantix with approx €3m invested? 2023-11-01
Cambrium–SEVERAL: investment, 202311 seed financing round €8m led by Essential Capital 2023-11-01
Cambrium–SNR: investment, 202311 seed financing round totalling €8m incl co-investor SNR 2023-11-01
Cambrium–Valor Equity Partners: investment, 202311 seed financing round totalling €8m incl co-investor Valor Equity Partners 2023-11-01
LimFlow–Inari Medical: investment, 202311– acquisition $250m cash upfront at closing + $165m by Inari Medical 2023-11-01
MeiraGTx–Sanofi: investment, 202310 strategic investment $30m with 4m ordinary shares at $7.5/share incl right of first negotation for some assets 2023-10-30
Merck (DE)–Hengrui: cancer drugs, 202310– strategic alliance €160m upfront + total up to €1.4b license HRS-1167 + option SHR-A1904 ww excl China 2023-10-30
CMBlu Energy–STRABAG: investment, 202310 equity investment €100m in connection with preferred partnership agreement 2023-10-23
FarmInsect–Bavaria (govt): investment, 202310 financing round Series A totalling €8m incl existing + co-investor Bayern Kapital 2023-10-23
FarmInsect–EU (govt): investment, 202310 financing round Series A totalling €8m incl new + co-investor EIC Fund 2023-10-23
FarmInsect–High-Tech Gründerfonds: investment, 202310 financing round Series A totalling €8m incl existing + co-investor HTGF 2023-10-23
FarmInsect–Minderoo Foundation: investment, 202310 financing round Series A totalling €8m incl new + co-investor MF Strategic Impact Fund 2023-10-23
FarmInsect–Sandwater: investment, 202310 financing round Series A totalling €8m incl new + lead investor Sandwater 2023-10-23
FarmInsect–SEVERAL: investment, 202310 financing round Series A €8m led by Sandwater 2023-10-23
FarmInsect–TU Munich: investment, 202310 financing round Series A totalling €8m incl existing + co-investor UnternehmerTUM Funding for Innovators 2023-10-23
STRABAG––CMBlu Energy: energy storage solutions, 202310– strategic collab preferred supplier agreement for SolidFlow batteries 2023-10-23
Biotech Austria–MC Services: public relations, 202310 service existent by MC Services 2023-10-17
BioNTech–MediLink Therapeutics: antibody-drug conjugates, 202310– collab + ww license excl China $70m upfront + $>1b milestones for anti-HER3 ADC 2023-10-12
Japan Tobacco–Max Planck: drug discovery, 202310– collab up to 7 years with Lead Discovery Center + its academic network 2023-10-11
AstronauTx–SEVERAL: investment, 202310 financing round Series A £48m led by Novartis Venture Fund 2023-10-09
LimmaTech Biologics–SEVERAL: investment, 202310 financing round Series A $37m co-led by Adjuvant Capital + AXA IM Alts + Novo REPAIR Impact Fund 2023-10-09
United Kingdom (govt)–Siemens: PET/CT scanner, 202310–202304 supply 2 Biograph Vision Quadra PET/CT scanners by Siemens Healthineers to NPIP 2023-10-05
MIRO Analytical–Bruker: investment, 202310 majority investment €na by Bruker 2023-10-04
Orakl Oncology–SEVERAL: investment, 202310 financing round €3m led by Speedinvest with HCVC + Verve Ventures 2023-10-04
Point Biopharma–Lilly: investment, 202310–202312 cash tender offer $1.4b by Lilly at $12.5/share 2023-10-03
Kranus Health–A Round Capital: investment, 202310 financing round Series A expansion totalling approx $8.5m incl existing + co-investor A Round 2023-10-02
Kranus Health–CSS (CH): investment, 202310 financing round Series A expansion totalling approx $8.5m incl new + co-lead investor SwissHealth Ventures 2023-10-02
Kranus Health–High-Tech Gründerfonds: investment, 202310 financing round Series A expansion totalling approx $8.5m incl existing + co-investor HTGF 2023-10-02
Kranus Health–Karista: investment, 202310 financing round Series A expansion totalling approx $8.5m incl existing + co-lead investor Karista 2023-10-02
Kranus Health–SEVERAL: investment, 202310 financing round Series A expansion approx $8.5m bringing total Series A to $15m 2023-10-02
Kranus Health–Wenvest: investment, 202310 financing round Series A expansion totalling approx $8.5m incl existing + co-investor Wenvest 2023-10-02
Refeyn–Alto Marketing: public relations, 202310 service existent by Alto Marketing Ltd 2023-10-02
AexeRNA Therapeutics–BioNTech: investment, 202310 acquisition €na of AexeRNA by BioNTech 2023-10-01
MetrioPharm–SEVERAL: investment, 202310c financing round Series D 1st closing CHF18m 2023-10-01
Alentis Therapeutics–Kyan Technologies: drug discovery technology, 202309– collab using Optim.AI + PD3D technologies for Claudin-1 expression research 2023-09-29
Nagi Bioscience–Excellis: investment, 202309 financing round Series A totalling CHF12.4m incl new + co-investor Excellis Holding 2023-09-28
Nagi Bioscience–imec: investment, 202309 financing round Series A totalling CHF12.4m incl new + co-lead investor imec.xpand 2023-09-28
Nagi Bioscience–SEVERAL: investment, 202309 financing round Series A CHF12.4m co-led by Swisscanto + imec.xpand 2023-09-28
Nagi Bioscience–Verve Capital Partners: investment, 202309 financing round Series A totalling CHF12.4m incl existing + co-investor Verve Ventures 2023-09-28
Nagi Bioscience–Zürcher Kantonalbank: investment, 202309 financing round Series A totalling CHF12.4m incl existing + co-investor ZKB 2023-09-28
Nagi Bioscience–Zürcher Kantonalbank: investment, 202309 financing round Series A totalling CHF12.4m incl new + co-lead investor Swisscanto 2023-09-28
4SC–Optimum Strategic Communications: public relations, 202309 service existent by Optimum 2023-09-27
Kern Tec–EU (govt): investment, 202309 financing round Series A totalling €12m incl co-investor EIC Fund 2023-09-27
Kern Tec–PeakBridge: investment, 202309 financing round Series A totalling €12m incl co-investor PeakBridge Growth 2 fund 2023-09-27
Kern Tec–SEVERAL: investment, 202309 financing round Series A €12m led by Telos Impact (eventually total includes grants?) 2023-09-27
Kern Tec–Telos Impact: investment, 202309 financing round Series A totalling €12m incl lead investor Telos Impact 2023-09-27
Co.faktor–Cytel: investment, 202309 acquisition of Co.faktor GmbH by Cytel Inc 2023-09-26
next pagenext page 1 2 3 4 ... 33 34 35  next pagenext page



Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture EBD Group World of Partnering Opportunities 650x300px

» top